SCHEMBL1717030

SCHEMBL1717030

CCOC(=O)C1CCN(Cc2c(C(=O)NC(CC)c3ccccc3)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ATM Q13315 1/20 0.45
TACR2 P21452 5/20 0.44
TACR3 P29371 5/20 0.44
OPRM1 P35372 4/20 0.44
CCR8 P51685 1/20 0.44
TP53 P04637 1/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1717416 0.91 TACR3 (0.47) ALDH1A1KDM4EHSD17B10TACR2TACR3
SCHEMBL1717021 0.91 ALDH1A1 (0.50) ALDH1A1KDM4EMAPK1ATMTACR2
SCHEMBL1718399 0.89 TACR3 (0.43) KMT2AMEN1ALDH1A1MAPK1ATM
SCHEMBL1717153 0.89 TACR3 (0.43) KMT2AMEN1TACR2TACR3OPRM1
SCHEMBL1718029 0.88 TACR3 (0.47) ALDH1A1KDM4EHSD17B10TACR2TACR3
SCHEMBL1717716 0.88 TACR3 (0.47) ALDH1A1KDM4EHSD17B10TACR2TACR3
SCHEMBL1716895 0.87 TACR3 (0.45) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL1717594 0.87 TACR3 (0.46) TACR2TACR3OPRM1
SCHEMBL1719397 0.87 TACR3 (0.45) TACR2TACR3OPRM1
SCHEMBL1718723 0.86 TACR3 (0.46) ALDH1A1KDM4EHSD17B10TACR2TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 KMT2A 1850/4885MEN1 3960/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.